Evidence map›Paper›PMID 31865522›Full record

ReviewInternal and emergency medicine2020

Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits.

Giuliano Tocci, Barbara Citoni, Vivianne Presta, Giovanna Leoncini, Francesca Viazzi, Barbara Bonino, Massimo Volpe, Roberto Pontremoli

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Internal and emergency medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2021
    Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Giuliano TocciHypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.ORCID 0000-0002-0635-4921
Barbara CitoniHypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.
Vivianne PrestaHypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.ORCID 0000-0002-2395-7572
Giovanna LeonciniDepartment of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132, Genoa, Italy.ORCID 0000-0001-7539-9464
Francesca ViazziDepartment of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132, Genoa, Italy.ORCID 0000-0003-4219-7043
Barbara BoninoDepartment of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132, Genoa, Italy.
Massimo VolpeHypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.ORCID 0000-0002-9642-8380
Roberto PontremoliDepartment of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132, Genoa, Italy. roberto.pontremoli@unige.it.ORCID 0000-0003-1238-872X
Ospedale Policlinico San Martino · ITIstituto Neurologico Mediterraneo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease is a worldwide health problem often burdened by severe cardiovascular complications. Hypertension represents one of the most important risk factor in affecting cardiovascular profile of chronic kidney disease patients. Since renin-angiotensin-aldosterone system plays a major role in determining cardiovascular outcome, guidelines recommend the use of renin-angiotensin-aldosteron inhibitors in order to control hypertension.

Indexed as

Angiotensin Receptor AntagonistsCardiovascular DiseasesHeartHumansHypertensionKidneyRenal Insufficiency, ChronicRenin-Angiotensin SystemRisk FactorsAngiotensin Receptor AntagonistsCardiovascular riskHypertensionRenin-angiotensin-aldosterone

Identifiers

PMID31865522
OpenAlexW2995196920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.